Olatoyosi Odenike to Molecular Targeted Therapy
This is a "connection" page, showing publications Olatoyosi Odenike has written about Molecular Targeted Therapy.
Connection Strength
0.510
-
The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib. Curr Hematol Malig Rep. 2020 12; 15(6):409-418.
Score: 0.164
-
A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis. Leukemia. 2017 02; 31(2):393-402.
Score: 0.121
-
T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia. Oncotarget. 2015 Oct 20; 6(32):33410-25.
Score: 0.115
-
Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015 Mar 01; 33(7):786-809.
Score: 0.109